Replies to post #51937 on Biotech Values

[rfj1862]

>Any cardiologists or knowlegable folks on statins have any thoughts regarding this UK finding, as well as any other information on this subject.<

Well, I'm not a cardiologist, but I have worked on the clinical, regulatory, and scientific aspects of a broad range of lipid-lowering agents for quite a while now.

It's pretty clear to me that the increase in risk associated with switching from Lipitor to Simvastatin is driven purely by changes in lipid levels rather than something intrinsic to atorvastatin. Simply put, simvastatin is a less effective lipid-lowering agent than Lipitor. You should be fine on Vytorin.